PROCEPT BioRobotics Corp PRCT
We are a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. We develop, manufacture and sell the AquaBeam Robotic System and HYDROS Robotic System, which are advanced, image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. BPH is the most common prostate disease and impacts approximately 40 million men in the United States. Each of our robotic systems employs a single-use disposable handpiece to deliver our proprietary Aquablation therapy, which combines real-time, multi-dimensional imaging, personalized treatment planning, automated robotics and heat-free waterjet ablation for targeted and rapid removal of prostate tissue. We designed our robotic systems to enable consistent and reproducible BPH surgery outcomes. We believe that Aquablation therapy represents a paradigm shift in the surgical treatment of BPH by addressing compromises associated with alternative surgical interventions. We designed Aquablation therapy to deliver effective, safe and durable outcomes for males suffering from lower urinary tract symptoms, or LUTS, due to BPH that is independent of prostate size and shape, and delivers resection independent of surgeon experience. We have developed a significant and growing body of clinical evidence, which includes nine clinical studies and over 150 peer-reviewed publications, supporting the benefits and clinical advantages of Aquablation therapy. As of December 31, 2025, we had an install base of 912 AquaBeam Robotic Systems and HYDROS Robotic Systems globally, including 718 in the United States.
Valuation FY2025 figures against the last close
Where the revenue comes from as reported in the latest 10-K
Revenue by geography
- U.S.
- Non-US
| Region | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| U.S. | $270.4M | $200.5M | $124.3M |
| Non-US | $37.7M | $24.0M | $11.9M |
As the company reported it, from the “Geographical Information (Details)” note of its latest 10-K. Every figure here has been checked against the total revenue the same filing reported. Regions are the filer's own and are not mapped onto a standard list — one company's “Americas” and another's “United States” are different areas, and making them look comparable would mean making at least one of them wrong. Slices under 1% are folded into “Other”.
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | $308.1M | $224.5M | $136.2M | $75.0M | $34.5M | $7.7M | — |
| Cost of revenue | $111.8M | $87.4M | $65.1M | $37.9M | $18.6M | $9.0M | — |
| Gross profit | $196.2M | $137.1M | $71.0M | $37.1M | $15.9M | -$1.3M | — |
| R&D | $71.3M | $62.3M | $48.4M | $29.0M | $19.0M | $16.3M | — |
| SG&A | $228.8M | $171.4M | $131.8M | $88.8M | $51.0M | $30.3M | — |
| Total operating expenses | $300.1M | $233.7M | $180.2M | $117.8M | $70.0M | $46.5M | — |
| Operating income | -$103.9M | -$96.6M | -$109.2M | -$80.7M | -$54.2M | -$47.8M | — |
| Interest expense | $3.6M | $4.2M | $4.0M | $5.2M | $5.8M | $5.3M | — |
| Pre-tax income | -$95.4M | -$91.0M | -$105.8M | -$87.2K | -$59.9K | -$53.0M | — |
| Income tax | $190.0K | $368.0K | $80.0K | $0 | $0 | $0 | — |
| Net income | -$95.6K | -$91.4K | -$105.9K | -$87.2K | -$59.9K | -$53.0M | — |
| EPS, basic | -1.72 | -1.75 | -2.24 | -1.96 | -3.63 | -14.47 | — |
| EPS, diluted | -1.72 | -1.75 | -2.24 | -1.96 | -3.63 | -14.47 | — |
| Shares, diluted (wtd. avg.) | 55.5M | 52.1M | 47.3M | 44.4M | 16.5M | 3.7M | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash and equivalents | $286.5M | $333.7M | $257.2M | $225.7M | $305.1M | $100.9M | $42.7M |
| Receivables | $83.5M | $83.5M | $48.4M | $15.3M | $4.5M | $1.5M | — |
| Inventory | $70.7M | $56.2M | $39.8M | $28.5M | $13.1M | $6.9M | — |
| Total current assets | $450.4M | $481.8M | $350.6M | $272.6M | $326.2M | $110.3M | — |
| Property, plant and equipment | $30.4M | $26.7M | $28.7M | $8.7M | $5.0M | $8.3M | — |
| Total assets | $508.1M | $534.0M | $404.7M | $309.3M | $337.0M | $126.0M | — |
| Accounts payable | $17.3M | $10.0M | $13.5M | $9.4M | $2.0M | $1.2M | — |
| Short-term debt | — | — | — | — | $0 | $4.6M | — |
| Total current liabilities | $65.8M | $53.1M | $45.9M | $35.3M | $16.2M | $14.5M | — |
| Long-term debt | $51.6M | $51.5M | $51.3M | $51.2M | $50.0M | $44.4M | — |
| Total liabilities | $142.2M | $131.8M | $124.0M | $112.3M | $69.9M | $65.0M | — |
| Retained earnings | -$641.6M | -$546.0M | -$454.6M | -$348.7M | -$261.5M | -$201.7M | — |
| Total equity | $365.9M | $402.2M | $280.8M | $197.1M | $267.1M | -$182.9M | -$143.8M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -$49.0M | -$99.2M | -$108.0M | -$80.4M | -$57.3M | -$48.3M | — |
| Depreciation and amortisation | $6.4M | $5.2M | $3.8M | $2.8M | $3.3M | $2.9M | — |
| Stock-based compensation | $47.6M | $31.8M | $19.1M | $10.3M | $3.8M | $2.2M | — |
| Capital expenditure | $9.4M | $4.4M | $25.2M | $2.7M | $592.0K | $233.0K | — |
| Investing cash flow | -$9.4M | -$4.4M | -$25.2M | -$2.7M | -$592.0K | -$233.0K | — |
| Financing cash flow | $11.2M | $180.1M | $167.8M | $3.6M | $262.1M | $106.8M | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001588978-26-000017.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Revenue | — | $7.7M | $34.5M | $75.0M | $136.2M | $224.5M | $308.1M |
| Gross profit | — | -$1.3M | $15.9M | $37.1M | $71.0M | $137.1M | $196.2M |
| Net income | — | -$53.0M | -$59.9K | -$87.2K | -$105.9K | -$91.4K | -$95.6K |
Recent filings and events
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Results announced Item 2.02
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Results announced Item 2.02
- Results announced Item 2.02
- Officer or director change Item 5.02
- Results announced Item 2.02
- Results announced Item 2.02
- Officer or director change Item 5.02
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 3841
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| SYK | STRYKER CORP | $117.81B | 36.6x | 11.2% |
| MMM | 3M CO | $89.46B | 28.9x | 1.5% |
| BSX | BOSTON SCIENTIFIC CORP | $66.22B | 23.6x | 19.9% |
| BDX | BECTON DICKINSON & CO | $54.18B | 34.2x | 8.2% |
| RMD | RESMED INC | $36.48B | 24.2x | 9.9% |
| DXCM | DEXCOM INC | $29.41B | 37.3x | 15.6% |
| MDLN | Medline Inc. | $29.20B | — | 11.5% |
| WST | WEST PHARMACEUTICAL SERVICES INC | $27.60B | 57.8x | 6.3% |